"In summary, animal models of human diseases indicate that psychedelics in general, and (R)-DOI in particular, may be an effective therapy for asthma, atherosclerosis, coronary artery disease, and inflammatory bowel disease. There are several other inflammatory conditions that we believe also may benefit from (R)-DOI therapy, including rheumatoid arthritis and diabetes."

"If continuing clinical studies further validate the use of psychedelic-assisted therapy for all of the above-discussed CNS indications, it begs the question, “How can the same single treatment approach lead to improvement in such a diverse range of dysfunctions?” This question deserves serious consideration, which we shall now attempt to address, and is at the core of what is suggested in the title as “a new paradigm.” We emphasize that the ideas to be discussed here represent untested hypotheses, but are consistent with presently known results."